Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.

Dirkse A, Golebiewska A, Buder T, Nazarov PV, Muller A, Poovathingal S, Brons NHC, Leite S, Sauvageot N, Sarkisjan D, Seyfrid M, Fritah S, Stieber D, Michelucci A, Hertel F, Herold-Mende C, Azuaje F, Skupin A, Bjerkvig R, Deutsch A, Voss-Böhme A, Niclou SP.

Nat Commun. 2019 Apr 16;10(1):1787. doi: 10.1038/s41467-019-09853-z.

2.

Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis.

Sundstrøm T, Prestegarden L, Azuaje F, Aasen SN, Røsland GV, Varughese JK, Bahador M, Bernatz S, Braun Y, Harter PN, Skaftnesmo KO, Ingham ES, Mahakian LM, Tam S, Tepper CG, Petersen K, Ferrara KW, Tronstad KJ, Lund-Johansen M, Beschorner R, Bjerkvig R, Thorsen F.

Acta Neuropathol Commun. 2019 Apr 10;7(1):55. doi: 10.1186/s40478-019-0712-8.

3.

Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma.

Hossain JA, Latif MA, Ystaas LAR, Ninzima S, Riecken K, Muller A, Azuaje F, Joseph JV, Talasila KM, Ghimire J, Fehse B, Bjerkvig R, Miletic H.

Neuro Oncol. 2019 Apr 8. pii: noz060. doi: 10.1093/neuonc/noz060. [Epub ahead of print]

PMID:
30958558
4.

Therapeutic Effect of Cabazitaxel and Blood-Brain Barrier opening in a Patient-Derived Glioblastoma Model.

Sulheim E, Mørch Y, Snipstad S, Borgos SE, Miletic H, Bjerkvig R, Davies CL, Åslund AKO.

Nanotheranostics. 2019 Feb 7;3(1):103-112. doi: 10.7150/ntno.31479. eCollection 2019.

5.

Deciphering the complex role of thrombospondin-1 in glioblastoma development.

Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, Pineau R, Guérit S, Maitre M, Dedieu S, Jeanne A, Bailly S, Feige JJ, Miletic H, Rossi M, Bello L, Falciani F, Bjerkvig R, Bikfalvi A.

Nat Commun. 2019 Mar 8;10(1):1146. doi: 10.1038/s41467-019-08480-y.

6.

Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.

Mastrella G, Hou M, Li M, Stoecklein VM, Zdouc N, Volmar MNM, Miletic H, Reinhard S, Herold-Mende CC, Kleber S, Eisenhut K, Gargiulo G, Synowitz M, Vescovi AL, Harter PN, Penninger JM, Wagner E, Mittelbronn M, Bjerkvig R, Hambardzumyan D, Schüller U, Tonn JC, Radke J, Glass R, Kälin RE.

Cancer Res. 2019 May 1;79(9):2298-2313. doi: 10.1158/0008-5472.CAN-18-0881. Epub 2019 Feb 4.

PMID:
30718358
7.

Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.

Johannessen TC, Hasan-Olive MM, Zhu H, Denisova O, Grudic A, Latif MA, Saed H, Varughese JK, Røsland GV, Yang N, Sundstrøm T, Nordal A, Tronstad KJ, Wang J, Lund-Johansen M, Simonsen A, Janji B, Westermarck J, Bjerkvig R, Prestegarden L.

Int J Cancer. 2019 Apr 1;144(7):1735-1745. doi: 10.1002/ijc.31912. Epub 2018 Dec 11.

PMID:
30289977
8.

Matrine induces senescence of human glioblastoma cells through suppression of the IGF1/PI3K/AKT/p27 signaling pathway.

Zhou W, Wang J, Qi Q, Feng Z, Huang B, Chen A, Zhang D, Li W, Zhang Q, Bjerkvig R, Li X, Wang J.

Cancer Med. 2018 Sep;7(9):4729-4743. doi: 10.1002/cam4.1720. Epub 2018 Aug 5.

9.

Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy.

Wang J, Qi Q, Zhou W, Feng Z, Huang B, Chen A, Zhang D, Li W, Zhang Q, Jiang Z, Bjerkvig R, Prestegarden L, Thorsen F, Wang X, Li X, Wang J.

Autophagy. 2018;14(11):2007-2022. doi: 10.1080/15548627.2018.1501133. Epub 2018 Aug 17.

PMID:
30025493
10.

Six-Transmembrane Epithelial Antigen of Prostate 3 Predicts Poor Prognosis and Promotes Glioblastoma Growth and Invasion.

Han M, Xu R, Wang S, Yang N, Ni S, Zhang Q, Xu Y, Zhang X, Zhang C, Wei Y, Ji J, Huang B, Zhang D, Chen A, Li W, Bjerkvig R, Li X, Wang J.

Neoplasia. 2018 Jun;20(6):543-554. doi: 10.1016/j.neo.2018.04.002. Epub 2018 May 3.

11.

DNA methylation-based classification of central nervous system tumours.

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM.

Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.

12.

The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors.

Boyé K, Pujol N, D Alves I, Chen YP, Daubon T, Lee YZ, Dedieu S, Constantin M, Bello L, Rossi M, Bjerkvig R, Sue SC, Bikfalvi A, Billottet C.

Nat Commun. 2017 Nov 17;8(1):1571. doi: 10.1038/s41467-017-01686-y.

13.

Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.

Fack F, Tardito S, Hochart G, Oudin A, Zheng L, Fritah S, Golebiewska A, Nazarov PV, Bernard A, Hau AC, Keunen O, Leenders W, Lund-Johansen M, Stauber J, Gottlieb E, Bjerkvig R, Niclou SP.

EMBO Mol Med. 2017 Dec;9(12):1681-1695. doi: 10.15252/emmm.201707729.

14.

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.

Eskilsson E, Røsland GV, Solecki G, Wang Q, Harter PN, Graziani G, Verhaak RGW, Winkler F, Bjerkvig R, Miletic H.

Neuro Oncol. 2018 May 18;20(6):743-752. doi: 10.1093/neuonc/nox191. Review.

15.

Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination.

Zhang X, Xu R, Zhang C, Xu Y, Han M, Huang B, Chen A, Qiu C, Thorsen F, Prestegarden L, Bjerkvig R, Wang J, Li X.

J Exp Clin Cancer Res. 2017 Sep 5;36(1):118. doi: 10.1186/s13046-017-0588-z.

16.

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.

Atzori MG, Tentori L, Ruffini F, Ceci C, Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, Ricci Vitiani L, Pallini R, Navarra P, Bjerkvig R, D'Atri S, Lacal PM, Graziani G.

J Exp Clin Cancer Res. 2017 Aug 10;36(1):106. doi: 10.1186/s13046-017-0577-2.

17.

Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma.

Obad N, Espedal H, Jirik R, Sakariassen PO, Brekke Rygh C, Lund-Johansen M, Taxt T, Niclou SP, Bjerkvig R, Keunen O.

J Cereb Blood Flow Metab. 2018 Oct;38(10):1741-1753. doi: 10.1177/0271678X17714656. Epub 2017 Jun 19.

18.

Cathepsin L silencing increases As2O3 toxicity in malignantly transformed pilocytic astrocytoma MPA58 cells by activating caspases 3/7.

Primon M, Huszthy PC, Motaln H, Talasila KM, Miletic H, Atai NA, Bjerkvig R, Lah Turnšek T.

Exp Cell Res. 2017 Jul 1;356(1):64-73. doi: 10.1016/j.yexcr.2017.04.013. Epub 2017 Apr 12.

PMID:
28412241
19.

Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy.

Zhu H, Leiss L, Yang N, Rygh CB, Mitra SS, Cheshier SH, Weissman IL, Huang B, Miletic H, Bjerkvig R, Enger PØ, Li X, Wang J.

Oncotarget. 2017 Feb 14;8(7):12145-12157. doi: 10.18632/oncotarget.14553.

20.

The angiogenic switch leads to a metabolic shift in human glioblastoma.

Talasila KM, Røsland GV, Hagland HR, Eskilsson E, Flønes IH, Fritah S, Azuaje F, Atai N, Harter PN, Mittelbronn M, Andersen M, Joseph JV, Hossain JA, Vallar L, Noorden CJ, Niclou SP, Thorsen F, Tronstad KJ, Tzoulis C, Bjerkvig R, Miletic H.

Neuro Oncol. 2017 Mar 1;19(3):383-393. doi: 10.1093/neuonc/now175.

21.

Lentiviral HSV-Tk.007-mediated suicide gene therapy is not toxic for normal brain cells.

Hossain JA, Ystaas LR, Mrdalj J, Välk K, Riecken K, Fehse B, Bjerkvig R, Grønli J, Miletic H.

J Gene Med. 2016 Sep;18(9):234-43. doi: 10.1002/jgm.2895.

PMID:
27490042
22.

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.

Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO.

Mol Cancer Res. 2016 Oct;14(10):976-983. Epub 2016 Jul 18.

23.

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.

Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, Fritah S, Harter PN, Välk K, Al Hossain J, Joseph JV, Jahedi R, Saed HS, Piccirillo SG, Spiteri I, Leiss L, Euskirchen P, Graziani G, Daubon T, Lund-Johansen M, Enger PØ, Winkler F, Ritter CA, Niclou SP, Watts C, Bjerkvig R, Miletic H.

Neuro Oncol. 2016 Dec;18(12):1644-1655. Epub 2016 Jun 10. Erratum in: Neuro Oncol. 2016 Dec;18(12 ):e2.

24.

Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.

Bougnaud S, Golebiewska A, Oudin A, Keunen O, Harter PN, Mäder L, Azuaje F, Fritah S, Stieber D, Kaoma T, Vallar L, Brons NH, Daubon T, Miletic H, Sundstrøm T, Herold-Mende C, Mittelbronn M, Bjerkvig R, Niclou SP.

Oncotarget. 2016 May 31;7(22):31955-71. doi: 10.18632/oncotarget.7454.

25.

Experimental therapies: gene therapies and oncolytic viruses.

Hulou MM, Cho CF, Chiocca EA, Bjerkvig R.

Handb Clin Neurol. 2016;134:183-97. doi: 10.1016/B978-0-12-802997-8.00011-6. Review.

PMID:
26948355
26.

Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma.

Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, Miletic H, Sakariassen PØ, Weinstock A, Wagner A, Lindsay SL, Hock AK, Barnett SC, Ruppin E, Mørkve SH, Lund-Johansen M, Chalmers AJ, Bjerkvig R, Niclou SP, Gottlieb E.

Nat Cell Biol. 2015 Dec;17(12):1556-68. doi: 10.1038/ncb3272. Epub 2015 Nov 23.

27.

Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells.

Podergajs N, Motaln H, Rajčević U, Verbovšek U, Koršič M, Obad N, Espedal H, Vittori M, Herold-Mende C, Miletic H, Bjerkvig R, Turnšek TL.

Oncotarget. 2016 Jan 5;7(1):593-609. doi: 10.18632/oncotarget.5477.

28.

Correction: Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression.

Huszthy PC, Sakariassen PØ, Espedal H, Brokstad KA, Bjerkvig R, Miletic H.

PLoS One. 2015 Oct 2;10(10):e0140303. doi: 10.1371/journal.pone.0140303. eCollection 2015. No abstract available.

29.

Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression.

Huszthy PC, Sakariassen PØ, Espedal H, Brokstad KA, Bjerkvig R, Miletic H.

PLoS One. 2015 Aug 20;10(8):e0136089. doi: 10.1371/journal.pone.0136089. eCollection 2015. Erratum in: PLoS One. 2015;10(10):e0140303.

30.

Practical Considerations for Omics Experiments in Biomedical Sciences.

Vaudel M, Barsnes H, Bjerkvig R, Bikfalvi A, Selheim F, Berven FS, Daubon T.

Curr Pharm Biotechnol. 2016;17(1):105-14. Review.

PMID:
26278526
31.

Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM).

Demeure K, Fack F, Duriez E, Tiemann K, Bernard A, Golebiewska A, Bougnaud S, Bjerkvig R, Domon B, Niclou SP.

Mol Cell Proteomics. 2016 Feb;15(2):481-92. doi: 10.1074/mcp.M115.052423. Epub 2015 Aug 4.

32.

Intercellular transfer of transferrin receptor by a contact-, Rab8-dependent mechanism involving tunneling nanotubes.

Burtey A, Wagner M, Hodneland E, Skaftnesmo KO, Schoelermann J, Mondragon IR, Espedal H, Golebiewska A, Niclou SP, Bjerkvig R, Kögel T, Gerdes HH.

FASEB J. 2015 Nov;29(11):4695-712. doi: 10.1096/fj.14-268615. Epub 2015 Jul 28.

PMID:
26220176
33.

Inference of Low and High-Grade Glioma Gene Regulatory Networks Delineates the Role of Rnd3 in Establishing Multiple Hallmarks of Cancer.

Clarke K, Daubon T, Turan N, Soulet F, Mohd Zahari M, Ryan KR, Durant S, He S, Herbert J, Ankers J, Heath JK, Bjerkvig R, Bicknell R, Hotchin NA, Bikfalvi A, Falciani F.

PLoS Genet. 2015 Jul 1;11(7):e1005325. doi: 10.1371/journal.pgen.1005325. eCollection 2015 Jul.

34.

Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.

Sanzey M, Abdul Rahim SA, Oudin A, Dirkse A, Kaoma T, Vallar L, Herold-Mende C, Bjerkvig R, Golebiewska A, Niclou SP.

PLoS One. 2015 May 1;10(5):e0123544. doi: 10.1371/journal.pone.0123544. eCollection 2015.

35.

Melanoma brain metastasis is independent of lactate dehydrogenase A expression.

Sundstrøm T, Espedal H, Harter PN, Fasmer KE, Skaftnesmo KO, Horn S, Hodneland E, Mittelbronn M, Weide B, Beschorner R, Bender B, Rygh CB, Lund-Johansen M, Bjerkvig R, Thorsen F.

Neuro Oncol. 2015 Oct;17(10):1374-85. doi: 10.1093/neuonc/nov040. Epub 2015 Mar 19.

36.

Whole genomes redefine the mutational landscape of pancreatic cancer.

Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM.

Nature. 2015 Feb 26;518(7540):495-501. doi: 10.1038/nature14169.

37.

Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas.

Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, Mittelbronn M, Bähr O, Weyerbrock A, Stuhr L, Miletic H, Sakariassen PØ, Stieber D, Rygh CB, Lund-Johansen M, Zheng L, Gottlieb E, Niclou SP, Bjerkvig R.

Acta Neuropathol. 2015 Jan;129(1):115-31. doi: 10.1007/s00401-014-1352-5. Epub 2014 Oct 17.

38.

Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies.

Keunen O, Taxt T, Grüner R, Lund-Johansen M, Tonn JC, Pavlin T, Bjerkvig R, Niclou SP, Thorsen F.

Adv Drug Deliv Rev. 2014 Sep 30;76:98-115. doi: 10.1016/j.addr.2014.07.010. Epub 2014 Jul 28. Review.

39.

Identification of a novel lytic peptide for the treatment of solid tumours.

Szczepanski C, Tenstad O, Baumann A, Martinez A, Myklebust R, Bjerkvig R, Prestegarden L.

Genes Cancer. 2014 May;5(5-6):186-200.

40.

In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.

Daphu I, Horn S, Stieber D, Varughese JK, Spriet E, Dale HA, Skaftnesmo KO, Bjerkvig R, Thorsen F.

Int J Mol Sci. 2014 May 16;15(5):8773-94. doi: 10.3390/ijms15058773.

41.

U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells.

Torsvik A, Stieber D, Enger PØ, Golebiewska A, Molven A, Svendsen A, Westermark B, Niclou SP, Olsen TK, Chekenya Enger M, Bjerkvig R.

Cancer Med. 2014 Aug;3(4):812-24. doi: 10.1002/cam4.219. Epub 2014 May 8.

42.

Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers?

van Lith SA, Navis AC, Verrijp K, Niclou SP, Bjerkvig R, Wesseling P, Tops B, Molenaar R, van Noorden CJ, Leenders WP.

Biochim Biophys Acta. 2014 Aug;1846(1):66-74. doi: 10.1016/j.bbcan.2014.04.004. Epub 2014 Apr 18. Review.

PMID:
24747768
43.

Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?

Fathpour P, Obad N, Espedal H, Stieber D, Keunen O, Sakariassen PØ, Niclou SP, Bjerkvig R.

Neuro Oncol. 2014 May;16(5):754-6. doi: 10.1093/neuonc/nou013.

44.

Tumor versus stromal cells in culture--survival of the fittest?

Talasila KM, Brekka N, Mangseth K, Stieber D, Evensen L, Rosland GV, Torsvik A, Wagner M, Niclou SP, Mahesparan R, Vintermyr OK, Bjerkvig R, Nigro JM, Miletic H.

PLoS One. 2013 Dec 2;8(12):e81183. doi: 10.1371/journal.pone.0081183. eCollection 2013.

45.

Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF.

Podergajs N, Brekka N, Radlwimmer B, Herold-Mende C, Talasila KM, Tiemann K, Rajcevic U, Lah TT, Bjerkvig R, Miletic H.

Radiol Oncol. 2013 Oct 8;47(4):330-7. doi: 10.2478/raon-2013-0063. eCollection 2013.

46.

Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.

Stieber D, Golebiewska A, Evers L, Lenkiewicz E, Brons NH, Nicot N, Oudin A, Bougnaud S, Hertel F, Bjerkvig R, Vallar L, Barrett MT, Niclou SP.

Acta Neuropathol. 2014 Feb;127(2):203-19. doi: 10.1007/s00401-013-1196-4. Epub 2013 Oct 24.

47.

Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.

Eisenreich S, Abou-El-Ardat K, Szafranski K, Campos Valenzuela JA, Rump A, Nigro JM, Bjerkvig R, Gerlach EM, Hackmann K, Schröck E, Krex D, Kaderali L, Schackert G, Platzer M, Klink B.

PLoS One. 2013 Sep 27;8(9):e76623. doi: 10.1371/journal.pone.0076623. eCollection 2013.

48.

Loss of adipocyte specification and necrosis augment tumor-associated inflammation.

Wagner M, Bjerkvig R, Wiig H, Dudley AC.

Adipocyte. 2013 Jul 1;2(3):176-83. doi: 10.4161/adip.24472. Epub 2013 Apr 19.

49.

Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids.

Primon M, Huszthy PC, Motaln H, Talasila KM, Torkar A, Bjerkvig R, Lah Turnšek T.

Exp Cell Res. 2013 Oct 15;319(17):2637-48. doi: 10.1016/j.yexcr.2013.08.011. Epub 2013 Aug 19.

PMID:
23968587
50.

Gene set based integrated data analysis reveals phenotypic differences in a brain cancer model.

Petersen K, Rajcevic U, Abdul Rahim SA, Jonassen I, Kalland KH, Jimenez CR, Bjerkvig R, Niclou SP.

PLoS One. 2013 Jul 9;8(7):e68288. doi: 10.1371/journal.pone.0068288. Print 2013.

Supplemental Content

Loading ...
Support Center